99% Purity CAS 866460-33-5 Setipiprant Hair Regrowth Setipiprant Powder Treatment Hair Loss Setipipiprant

Basic Info

Model NO.	D-sung Setipiprant
Type	Hair Loss Treatment
Function	Hair Loss Treatment
Main Ingredient	Hair Loss Treatment
Group	Person Who Loss Their Hair
Certification	CE, FDA, EEC, MSDS, GMP
Quality Guarantee Period	Two Years
Store Method	Normal Temperature
Product Name	Setipiprant
Name	Setipiprant Powder
appearance	White Powder
Color	White
Store	Cool and Dry
Grade	Cosmetics Grade
Assay	HPLC 99%
Application	Hair Loss Treatment
Specific	COA
Test Method	HPLC
Shelf Life	2 Years
Density	1.4±0.1 g/cm3
Mf	C24h19fn2o3
MW	402.418
Boiling Point	690.4±55.0 °c
Transport Package	Negotiable
Specification	99%
Trademark	D-sung
Origin	Shaanxi Xi′an
Production Capacity	1000kg/Month

Product Description

99% Purity CAS 866460-33-5 Setipiprant Hair Regrowth Setipiprant Powder Treatment Hair Loss Setipipiprant

99% Purity CAS 866460-33-5 Setipiprant Hair Regrowth Setipiprant Powder Treatment Hair Loss SetipipiprantProduct Description

99% Purity CAS 866460-33-5 Setipiprant Hair Regrowth Setipiprant Powder Treatment Hair Loss Setipipiprant

Product Details

99% Purity CAS 866460-33-5 Setipiprant Hair Regrowth Setipiprant Powder Treatment Hair Loss Setipipiprant

Product name	Setipiprant
Cas number	866460-33-5
Apperance	White powder
Density	1.4±0.1 g/cm3
MF	C24H19FN2O3
MW	402.418

Setipiprant is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.A phase 2A study is underway to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo and the active comparator, finasteride, in 18 to 41 years old males with androgenetic alopecia.
Application&Function

99% Purity CAS 866460-33-5 Setipiprant Hair Regrowth Setipiprant Powder Treatment Hair Loss Setipipiprant

1. Increase cellular proliferation of outer root sheeth cells.2. Increase hair diameter and hair density.3. Increase the percentage of hair in the anagen phase.4. Exert no negative effect on body hormone levels.5. Provide equivalent or better net growth than Finasteride.
Specification

Products

99% Purity CAS 866460-33-5 Setipiprant Hair Regrowth Setipiprant Powder Treatment Hair Loss Setipipiprant

Basic Info

Product Description